Intrinsic Value of S&P & Nasdaq Contact Us

SCYNEXIS, Inc. SCYX NASDAQ

NASDAQ Global Market • Healthcare • Drug Manufacturers - Specialty & Generic • US • USD

SharesGrow Score
65/100
3/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

SCYNEXIS, Inc. (SCYX) has a negative trailing P/E of -5.0, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -20.18%.

Criteria proven by this page:

  • VALUE (100/100, Pass) — composite valuation score exceeds the 60/100 pass threshold.
  • Trailing Earnings Yield -20.18% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings.

Overall SharesGrow Score: 65/100 with 3/7 criteria passed.

SharesGrow 7-Criteria Score
65/100
SG Score
View full scorecard →
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
FUTURE
100/100
Analyst consensus
→ Forecast
PAST
25/100
→ Income
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
~
MOAT
50/100
→ Income
GROWTH
100/100
→ Income
INCOME
10/100
→ Income

Valuation Snapshot — SCYX

Valuation Multiples
P/E (TTM)-5.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.86
P/S Ratio2.12
EV/EBITDA1.5
Per Share Data
EPS (TTM)$-0.20
Book Value / Share$1.13
Revenue / Share$0.47
FCF / Share$-0.12
Yields & Fair Value
Earnings Yield-20.18%
Dividend Yield0.00%

Historical Valuation

Year P/E (TTM) PEG Ratio P/B Ratio P/S Ratio Dividend Yield
2016 -2.0 0.05 1.74 236.27 -
2017 -2.5 0.06 2.90 241.45 -
2018 -1.7 0.02 0.68 82.30 -
2019 -1.0 0.00 3.96 421.77 -
2020 -1.5 0.03 3.60 0.00 -
2021 -4.9 0.06 3.90 12.23 -
2022 -1.1 -0.06 20.56 13.06 -
2023 1.6 -0.01 1.46 0.76 -
2024 -2.8 0.02 1.07 15.67 -
2025 -3.7 0.06 0.64 1.53 -

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year EPS (Diluted) Revenue Net Income Net Margin
2016 $-15.75 $257K $-29.99M -11668.9%
2017 $-9.37 $257K $-25.06M -9751%
2018 $-2.84 $257K $-12.47M -4851.4%
2019 $-9.85 $121K $-55.23M -45647.9%
2020 $-5.15 $0.00 $-55.19M -
2021 $-1.25 $13.16M $-32.87M -249.7%
2022 $-1.47 $5.09M $-62.81M -1233.7%
2023 $1.39 $140.14M $67.04M 47.8%
2024 $-0.44 $3.75M $-21.29M -568.3%
2025 $-0.17 $20.6M $-8.61M -41.8%

Analyst Estimates

Year EPS (Avg) EPS Range Revenue (Avg) Revenue Range Analysts
2026 $-0.49 $-0.75 – $-0.35 $1.15M $892.44K – $1.62M 2
2027 $-0.33 $-0.50 – $-0.23 $6.68M $5.16M – $9.38M 2
2028 $-0.29 $-0.46 – $-0.11 $14.08M $14.08M – $14.08M 3
2029 $-0.35 $-0.53 – $-0.25 $13.45M $10.4M – $18.9M 1
2030 $-0.08 $-0.11 – $-0.05 $36.5M $28.23M – $51.27M 1
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message